A new trading day began on Monday, with Outlook Therapeutics Inc (NASDAQ: OTLK) stock price down -10.19% from the previous day of trading, before settling in for the closing price of $2.06. OTLK’s price has ranged from $0.87 to $12.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Meanwhile, its annual earnings per share averaged 48.72%. With a float of $21.17 million, this company’s outstanding shares have now reached $23.91 million.
Let’s look at the performance matrix of the company that is accounted for 23 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Outlook Therapeutics Inc (OTLK) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Outlook Therapeutics Inc is 33.82%, while institutional ownership is 26.85%. The most recent insider transaction that took place on Sep 26 ’24, was worth 28,446. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $5.69, taking the stock ownership to the 5,946 shares. Before that another transaction happened on Mar 28 ’24, when Company’s Director bought 1,882 for $11.82, making the entire transaction worth $22,242. This insider now owns 5,049 shares in total.
Outlook Therapeutics Inc (OTLK) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 48.72% per share during the next fiscal year.
Outlook Therapeutics Inc (NASDAQ: OTLK) Trading Performance Indicators
Here are Outlook Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.51, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -0.30 in one year’s time.
Technical Analysis of Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics Inc (NASDAQ: OTLK) saw its 5-day average volume 0.81 million, a negative change from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 31.80%. Additionally, its Average True Range was 0.23.
During the past 100 days, Outlook Therapeutics Inc’s (OTLK) raw stochastic average was set at 13.30%, which indicates a significant increase from 10.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.52% in the past 14 days, which was lower than the 187.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.26, while its 200-day Moving Average is $5.86. Nevertheless, the first resistance level for the watch stands at $1.96 in the near term. At $2.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.16. If the price goes on to break the first support level at $1.76, it is likely to go to the next support level at $1.68. The third support level lies at $1.56 if the price breaches the second support level.
Outlook Therapeutics Inc (NASDAQ: OTLK) Key Stats
With a market capitalization of 59.16 million, the company has a total of 31,980K Shares Outstanding. Currently, annual sales are 0 K while annual income is -75,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was 5,690 K.
